Dean Clinic Makes Donation to Local Schools to Help Children With Life ... - MarketWatch (press release) |
Dean Clinic Makes Donation to Local Schools to Help Children With Life ... MarketWatch (press release) MADISON , Wis., Jan 30, 2012 (GlobeNewswire via COMTEX) -- Dean Clinic and pharmaceutical company Dey Pharma, have teamed up to make Madison schools safer for children with allergies. For the 2011-2012 school year, more than 40 EpiPens were donated, ...
and more » |
ISTA completes patient enrollment in Phase II allergic rhinitis study - Pharmaceutical Business Review |
ISTA completes patient enrollment in Phase II allergic rhinitis study Pharmaceutical Business Review ISTA Pharmaceuticals has completed patient enrollment in Phase II study of its BEPOSONE (bepotastine besilate - steroid combination nasal spray) for the treatment of symptoms associated with seasonal allergic rhinitis. The company has enrolled more ... ISTA Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of ...MarketWatch (press release) ISTA Pharma Closes Patient Enrollment In Phase 2 Trial Of BEPOSONE - Quick FactsRTT News
all 9 news articles » |
Allergic to the cold? A potentially life threatening allergy - WEAU-TV 13 |
Allergic to the cold? A potentially life threatening allergy WEAU-TV 13 Dr. Adela Taylor at Mayo Clinic Health System says reactions to cold allergies can vary widely from person to person. “Different people react at different temperatures, for some people they might react just below 50 degrees other people it may be ...
and more » |
NIAID, Aeras partner for new tuberculosis vaccine trial - Pharmaceutical Business Review |
NIAID, Aeras partner for new tuberculosis vaccine trial Pharmaceutical Business Review The National Institute of Allergy and Infectious Diseases (NIAID) has joined as a partner for a Phase II proof-of-concept trial of a tuberculosis vaccine jointly developed by Aeras and Crucell. The trial will evaluate the safety and efficacy of vaccine ... NIH to Join Multi-center Clinical Trial of New Tuberculosis VaccineMarketWatch (press release) NIH-funded HIV clinical research sites to join pediatric tuberculosis vaccine ...National Institutes of Health (press release)
all 16 news articles » |
Slapping On a Skin Patch to Combat Hay Fever - Wall Street Journal  Wall Street Journal |
Slapping On a Skin Patch to Combat Hay Fever Wall Street Journal By JEREMY SINGER-VINE Skin patches coated with allergens may be a more convenient and effective way to treat hay fever than current methods, according to a study in the Journal of Allergy and Clinical Immunology. Only about 5% of hay-fever sufferers ...
|
Ora Executives to Present at Allergy Drug Discovery & Development Conference ... - MarketWatch (press release) |
Ora Executives to Present at Allergy Drug Discovery & Development Conference ... MarketWatch (press release) Keith Lane will moderate a panel discussion on the Future Directions in Allergic Rhinitis with panelists Dr. Warren Carr, Associate Medical Director, Southern California Research; Dr. William Berger, MBA, Clinical Professor, Pediatrics, ...
and more » |
FRIENDS OF THE PLYMOUTH POUND: Feb. 1 - Daily News Transcript |
FRIENDS OF THE PLYMOUTH POUND: Feb. 1 Daily News Transcript She has a severe flea allergy that was not treated in her former home. Now her hair is growing back and Shadow would love nothing more than to sit on someone's lap in a quiet environment. She can be feisty, so should not live in to a home with small ...
and more » |
My Breakup with Unhealthy Eating - ChicagoNow (blog)  ChicagoNow (blog) |
My Breakup with Unhealthy Eating ChicagoNow (blog) Her practice, FEED â€" Forming Early Eating Decisions, specializes in pediatric nutrition and digestive diseases, including celiac disease and food allergies. Lara has more than nine years of experience in clinical practice at two of the top ranked ...
|
Soligenix Announces 1 for 20 Reverse-Split of its Common Stock - MarketWatch (press release) |
Soligenix Announces 1 for 20 Reverse-Split of its Common Stock MarketWatch (press release) RiVax(TM) has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. Both RiVax(TM) and SGX204 are currently the subject of a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant ...
and more » |
Infections of the Reproductive System: Human Papillomavirus - EmpowHer |
Infections of the Reproductive System: Human Papillomavirus EmpowHer The National Institute of Allergy and Infectious Diseases said that genital HPV is one of the most common sexually transmitted diseases. About 20 million Americans currently have HPV. WomensHealth.gov added that at least half of all sexually active men ...
and more » |